Matinas BioPharma appoints Eric J. Ende to board
Dr. Ende is a life sciences executive with over 20 years of financial leadership experience.
Dr. Ende currently serves as President of Ende BioMedical Consulting Group.
He also currently serves on the Technology Transfer Committee of Mount Sinai Innovation Partners.
Previously, Dr. Ende consulted with Icahn Enterprises in connection with their efforts to appoint board members at Forest Labs, Genzyme, Biogen IDEC, and Amylin.
From 2010 to 2011, Dr. Ende served as a Director on Genzyme’s Board until it was acquired by Sanofi-Aventis in 2011 for $20 billion.
During his tenure on Genzyme’s Board of Directors, he was a member of the Audit and Risk Management Committees.
From 2002 through 2008, Dr. Ende was the senior biotechnology analyst at Merrill Lynch.
From 2000 to 2002, he served as the senior biotechnology analyst at Bank of America Securities and, from 1997 to 2000, he served as a biotechnology analyst at Lehman Brothers.
Dr. Ende received his M.B.A. in Finance & Accounting from NYU – Stern Business School, an M.D. from Mount Sinai School of Medicine in 1994, and a BS in Biology and Psychology from Emory University in 1990. ■
LATEST MOVES FROM New Jersey
- Wireless Telecom Group appoints Daniel Monopoli as CTO
- New Jersey Resources names Maureen Borkowski to board
- Milestone Scientific appoints Daniel Goldberger as CEO
- Celldex changes management team
- Pacira Pharmaceuticals appoints Mark I. Froimson to board
More inside POST